Compare BioNano Genomics Inc (BNGO) vs MGM Resorts International (MGM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs MGM Resorts International — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.66M), while MGM Resorts International trades at $44.5 (market cap $11.10B). The key difference: MGM Resorts International is far larger — about 812.6× BioNano Genomics Inc's market cap, and MGM Resorts International pays a 0.03% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | MGM | |
|---|---|---|
Market Cap | $13.66M | $11.10B |
Sector | Health | Consumer Cyclical |
52-Week High | $4.92 | $50.69 |
52-Week Low | $1.06 | $30.72 |
Enterprise Value | $16.26M | $38.40B |
Dividend Yield | — | 0.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.
The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.
MGM Resorts International (MGM) trades at $43.915, up 1.28% on the day, with a bearish technical signal and neutral oscillators. Recent Q2 2026 earnings missed estimates at $0.59 per share versus $0.63 expected, though revenue hit a record. The company faces a shareholder investigation into Barry Diller's proposed acquisition at $48.30 per share. Fundamentals show a P/E of 26.75 and net income margin of 2.4%, with revenue growth to $17.54B in 2025.
The outlook is mixed: analyst consensus targets $51.14 with 49% buy ratings, but technicals and acquisition uncertainty pose risks. Upside hinges on Las Vegas recovery and BetMGM's iGaming expansion, while margin pressures and legal probes are headwinds. Cash flow trends improved to a projected net positive $572M in 2026, supporting stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About MGM Resorts International
MGM Resorts is the largest resort operator on the Las Vegas Strip with 35,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Cosmopolitan, Luxor, New York-New York, and CityCenter. The Strip contributed approximately 49% of total EBITDAR in the prepandemic year of 2019. MGM also owns U.S. regional assets, which represented 29% of 2019 EBITDAR. we estimate MGM's U.S. sports and iGaming operations are currently a mid-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM Macau casinos with a new property that opened on the Cotai Strip in early 2018. Further, we estimate MGM will open a resort in Japan in 2027.
Read more on MGM →
